Colistin, mechanisms and prevalence of resistance

Abstract

Background:

Infections caused by multi-drug-resistant Gram-negative bacteria, particularly Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae, that cause nosocomial infections, represent a growing problem worldwide. The rapid increase in the prevalence of Gram-negative pathogens that are resistant to fluoroquinolones and aminoglycosides as well as all β-lactams, including carbapenems, monobactam, cephalosporins and broad-spectrum penicillins, has prompted the reconsideration of colistin as a valid therapeutic option. Colistin is an old class of cationic, which act by disrupting the bacterial membranes resulting in cellular death. Although there has been a significant recent increase in the data gathered on colistin, focusing on its chemistry, antibacterial activity, mechanism of action and resistance, pharmacokinetics, pharmacodynamics and new clinical application, the prevalence of colistin resistance has been very little reported in the literature. This review concentrates on recent literature aimed at optimizing the clinical use of this important antibiotic.

Methods:

The available evidence from various studies (microbiological and clinical studies, retrieved from the PubMed, and Scopus databases) regarding the mechanisms and prevalence of resistance was evaluated.

Results:

Increasing use of colistin for treatment of infections caused by these bacteria has led to the emergence of colistin resistance in several countries worldwide. Although resistance to polymyxins is generally less than 10%, it is higher in the Mediterranean and South-East Asia (Korea and Singapore), where colistin resistance rates are continually increasing.

Conclusion:

There is a critical need for effective infection prevention and control measures and strict use of antibiotics in the world to control the rise and spread of colistin resistance.

Keywords: :

• Colistimethate sodium
• Colistin
• Colistin resistance
• MDR Gram-negative bacteria
• Polymyxin
• Prevalence

Transparency

Declaration of funding

This study was supported by a grant from the Drug Applied Research Center (Tabriz University of Medical Sciences) with Grant No. 93007782.

Declaration of financial/other relationships

A.Z.B. and H.S.K. have disclosed that they were recipients of the research grant named above.

CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

The authors thank all staff of educational hospitals for cooperation in antibiotic stewardships of Tabriz University of Medical Science. They also thank Dr. Hossein Navidinia for his helpful comments on manuscript.